Search alternatives:
point decrease » point increase (Expand Search)
teer decrease » greater decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
point decrease » point increase (Expand Search)
teer decrease » greater decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
42061
P4HA3 deficiency increased sensitization to immune checkpoint inhibitors and P4HA3 could predict the clinical therapeutic effect of PD-1 inhibitor (Camrelizumab).
Published 2024“…(B) P4HA3 deficiency inhibited proliferation ability of MDA-MB-231, HCT116 and A549 cell lines by EdU assay. Scale bar: 50 μm. …”
-
42062
Table_7_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX
Published 2024“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
-
42063
Table_13_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX
Published 2024“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
-
42064
Table_12_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX
Published 2024“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
-
42065
Living 3,4-Polymerization of Isoprene by Cationic Rare Earth Metal Alkyl Complexes Bearing Iminoamido Ligands
Published 2011“…The sterically crowded complexes <b>1</b>−<b>3</b> give a mixture of 3,4- and <i>trans</i>-1,4-polyisoprenes (3,4-selectivities: 48−82%, <i>trans</i>-1,4-selectivities: 50−17%), whereas the less sterically demanding complexes <b>4</b>−<b>6</b> show high 3,4-selectivities (3,4-selectivities: 90−100%). …”
-
42066
DataSheet1_Insights into the reactivity and lithium plating mechanisms of ultra-thin metal oxide coatings for anode-free solid-state lithium metal batteries.docx
Published 2023“…Increasing Al<sub>2</sub>O<sub>3</sub> thickness decreases the practical current density compared to unmodified Cu (30 µA/cm<sup>2</sup>), but increasing ZnO thicknesses can double or triple this value. …”
-
42067
Table_14_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.XLSX
Published 2024“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
-
42068
Table_3_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.XLSX
Published 2024“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
-
42069
Table_11_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX
Published 2024“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
-
42070
Table_15_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.XLSX
Published 2024“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
-
42071
Loss of MLL1 in adult mice.
Published 2021“…<p>(A) Giemsa-stained sections from the femur of <i>Mll1</i><sup><i>FC/+; RC/+</i></sup> and <i>Mll1</i><sup><i>FC/FC; RC/+</i></sup> mice. …”
-
42072
Table_5_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX
Published 2024“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
-
42073
Data_Sheet_1_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.PDF
Published 2024“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
-
42074
Table_9_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX
Published 2024“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
-
42075
Table_4_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.XLSX
Published 2024“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
-
42076
Robotic-Assisted Median Arcuate Ligament Release With Celiac Artery Lysis and Celiac Ganglion Neurolysis
Published 2020“…<a href="https://doi.org/10.1016/j.jvs.2008.12.078"><em>J Vasc Surg</em>. 2009;50:124-133.…”
-
42077
A diabetic state promoted a uniform loss of linear heparan sulfate staining in the GBM independent of the treatment.
Published 2014“…This result was confirmed using a semiquantitative scoring system (E). The data represent the means ± SEMs. *<i>p<</i>0.0001 vs. groups. …”
-
42078
Image 3_CS Ratio is an immune-related prognostic biomarker for cervical cancer.tiff
Published 2025“…The CS polarization state reflects a highly coordinated network of pro-tumor anti-tumor variables offering a simplified yet effective immune response indicator for the complex TME. …”
-
42079
Intermittent fasting enhances long-term memory consolidation, adult hippocampal neurogenesis and expression of longevity gene Klotho (Microarray dataset)
Published 2021“…Relatively loose criteria were initially used to filter the data (to minimize analytical false negatives), but genes were required to pass these criteria for each of the four methods to be considered further (four out of four methods) to minimize analytical false positives. </p> <p>A fold change of 1.2 along with a t-test p-value of less than 0.05 was used in RMA and dChip, and a confidence of 50% or higher was used in the Drop Method. …”
-
42080
Image 2_CS Ratio is an immune-related prognostic biomarker for cervical cancer.tiff
Published 2025“…The CS polarization state reflects a highly coordinated network of pro-tumor anti-tumor variables offering a simplified yet effective immune response indicator for the complex TME. …”